What do we need to consider when it comes to remote self-sampling?
Kimia Sobhani, Jennifer Van Eyk |
The precision diagnostic tests that often inform essential treatment decisions can take years to develop and validate – and even then their applicability is often limited to specific indications. Companion diagnostics, for example, are useful for predicting safety- and efficacy-related responses to treatment, but may be considered niche in their window of application. Broader diagnostics that harness the utility of previously validated, well-studied circulating biomarkers can be used to address disease-specific diagnostic and prognostic questions, both in and out of the clinic.
Continuous or semi-continuous biomarker assessment relies on our existing knowledge of changing biomarker concentrations over time and/or in response to disease development. For many clinically established analytes, however, the expected shift in concentration over time is poorly defined, especially in early disease. These days, artificial intelligence can be applied to help pinpoint disease risk and progression from routine lab tests, and – in some cases – routine monitoring can enhance the power of these approaches.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.